73 results about "Dry eyes" patented technology

This application generally relates to stable peptide compositions and kits comprising low levels of buffering and chelating agents, and methods of using the same for the treatment of patients having moderate / severe or severe dry eye.

The present application provides compositions and methods for treatment of ocular inflammatory conditions, dry eye diseases, and abnormal corneal neovascularization, using etiprednol. In one example, a composition is provided comprising a semi-fluorinated alkane compound such as, e.g., perfluorohexyloctane; and an additive selected from paraffin, propylene glycol diacetate (PGD), a hydroxyalkyl ester of an aliphatic fatty acid, a hydroxyacid alkyl ester, an alkyl ester of a fatty acid, phenethyl alcohol, ethanol, isopropanol, glycerol, propylene glycol, polyethylene glycol, n-butanol, or combinations thereof. Eye drops comprising the compositions are also provided. Methods of using the compositions are also provided and include methods for reducing one or more symptoms of ocular inflammatory conditions, dry eye diseases, or abnormal corneal neovascularization.

The application provides a composition containing Omega 3, which comprises a conjugate formed by connecting Omega 3 and a PEDF-derived peptide. The PEDF-derived peptide is obtained by truncation on the basis of a full-length PEDF protein, and the amino acid sequence is shown as SEQ ID No. 1. The Omega 3 is EPA, and the conjugate is obtained by connecting the Omega 3 and the PEDF-derived peptide through a click chemistry method. The composition can promote eye health repair, especially the treatment and improvement of dry eye, and has a clinical application prospect.

The application provides an eye Tibetan medicine composition, a preparation and a preparation method and application thereof, and relates to the technical field of dry eye. The eye Tibetan medicine composition contains 80-120 parts by weight of berberis bark extract and 80-120 parts by weight of Qinghai dracocephalum extract. The eye preparation is prepared by mixing the eye Tibetan medicine composition and a solvent. The eye preparation can repair ocular surface tissue damage caused by dry eye and restore the normal secretion function of lacrimal glands.

The application discloses a tri-substituted tetrahydroisoquinoline amide derivative with a novel structure or a pharmaceutically acceptable salt thereof, which is a compound shown in formula I. The compound has a strong inhibiting capacity on immune cell migration, the compound itself has high permeability and good water solubility, and can be used as an immune cell migration inhibitor and used for developing a medicine for treating ophthalmic diseases such as dry eye.

This invention discloses the application of low-concentration topical anesthetics in ophthalmic surgery, relating to the field of low-concentration topical anesthetic application technology, including the following specific application process: confirming the patient's basic surgical condition before administration; selecting anesthetic drugs and optimizing the administration concentration; performing administration according to the specific situation; real-time dynamic monitoring and adjustment of the administration dosage; gradually reducing the drug and transitioning to withdrawal. This invention improves drug safety and patient compliance while ensuring analgesic effects by optimizing anesthetic drug concentration and administration method. Furthermore, by using topical anesthetics at concentrations lower than conventional anesthetics for local administration after ophthalmic surgery, it can effectively relieve postoperative pain, discomfort, and foreign body sensation while significantly reducing toxic effects on corneal epithelial cells, reducing delayed corneal healing, dry eye, and corneal damage. It is effectively applicable to analgesia management after pterygium excision, refractive surgery, and other common ophthalmic surgeries, and has good clinical application value.

This invention discloses a lutein-infused massage and care eye ointment containing precious Chinese medicinal herbs, free of eight major allergens, and suitable for all ages. Each tube contains 10 grams. The formula uses lutein as its core ingredient, combined with artificial musk, bear bile powder, pearl powder, ginseng, and Ganoderma lucidum, along with eye-protecting ingredients such as wolfberry, chrysanthemum, cassia seed, and buddleja flower. It is supplemented with sodium hyaluronate and vitamin B6, using medical-grade hypoallergenic petrolatum as a base. The ointment is strictly free of eight major allergens, making it safe and gentle, suitable for people aged 3 to 100. This invention features a simple process, can be industrially produced, and can effectively relieve eye fatigue, dry eyes, itchy eyes, bloodshot eyes, dark circles, eye bags, wrinkles, photophobia, and tearing in the wind, among other sub-healthy eye problems. It has extremely high market application and health care value.

This invention relates to ophthalmic compositions comprising troxerutin and a surfactant selected from polyoxyethylene 35 castor oil, polyoxyethylene 40 hydrogenated castor oil, polyoxyethylene (20) sorbitan monooleate, polyoxyethylene (20) sorbitan monolaurate, and mixtures thereof, wherein the weight ratio of troxerutin to the surfactant is from 0.02:1 to 100:1, wherein the surfactant is present in an amount of up to 7% by weight relative to the total weight of the composition, and wherein the composition is in the form of a solution, suspension, or gel. The invention also relates to the compositions for treating dry eye disease.

The utility model discloses an eye cane raw material straightening equipment, including steam straightening structure, steam straightening structure intercommunication steam recovery structure, steam straightening structure is adjusted the position of hot roll straightening subassembly through telescopic structure, steam straightening structure includes bottom box, and the straightening box is communicated in bottom box upside, and the left side of straightening box is fixed with first material guide roller, and steam straightening subassembly is installed in straightening box and is dismantled, and steam straightening subassembly includes steam box, and the position of steam spray header and first inverted U shape board second material guide roller on first support plate is adjusted through telescopic structure telescopic of steam box, and second material guide roller is located between steam spray header, and steam spray header is connected with steam generator through first gas pipe, and the downside of second material guide roller is provided with third material guide roller, and this eye cane raw material straightening equipment is handled to the high temperature steam straightening of the serious deformation and the relatively dry eye cane rattan cane through the setting of steam straightening subassembly, and the straightening of eye cane rattan cane is carried out again through the setting of hot roll straightening subassembly.

The application provides a traditional Chinese medicine preparation for treating dry eye, and a preparation method and application thereof, and belongs to the technical field of traditional Chinese medicine preparations. The traditional Chinese medicine preparation comprises the following components in parts by weight: 8-12 parts of chrysanthemum, 8-12 parts of cassia seed, and 8-12 parts of Coptis chinensis / Scutellaria baicalensis. The compatibility and synergistic effect of chrysanthemum, cassia seed and Coptis chinensis / Scutellaria baicalensis in the traditional Chinese medicine preparation, and the drug administration mode of atomization fumigation can make the drug directly act on the ocular surface, improve the local drug concentration, compared with the existing method of simply using sodium hyaluronate eye drops, the preparation can effectively improve the ocular surface inflammation, improve the tear film stability, and fundamentally relieve the core symptoms such as dryness and fatigue of dry eye.

The utility model provides a kind of for dry eye syndrome fumigation steaming hot compress portable physiotherapy device, comprising: seat body, the side wall of the seat body is formed with first recess, and its top is formed with second recess;Atomization structure, the atomization structure is detachably set in the first recess, it is used to change liquid into atomized gas, and the atomization structure includes upper and lower arrangement liquid storage tank and atomization component;Fumigation structure, the fumigation structure is connected with the atomization structure, for fumigation steaming atomized gas in eye position;Hot compress structure, the hot compress structure is detachably set in the second recess, for hot compress eye position after taking out.The utility model integrates atomization, fumigation and hot compress function, atomization structure converts liquid into atomized gas, fumigation structure is applied to eye, cooperate hot compress structure, can effectively alleviate dry eye syndrome patient eye dry and tired and other symptoms.

A moisture chamber adapted for use with eyeglasses. The moisture chamber is a single-use, disposable, component that is temporarily adhered to the inside of a the lens of a pair of glasses. The moisture chamber may be used on one or both of the lenses and works by creating a moist environment for the eye to help alleviate dry eyes. The moisture chamber may be made of silicon and may be 3-D printed.

This invention discloses the application of LGK974 in the preparation of drugs for the prevention and / or treatment of dry eye syndrome, relating to the field of biomedical technology. The application of LGK974 in the preparation of drugs for the prevention and / or treatment of dry eye syndrome. This invention is the first to discover the application of the Wnt-β-catenin pathway inhibitor LGK974 in the treatment of dry eye syndrome. LGK974, by inhibiting the Wnt-β-catenin pathway, can effectively protect meibomian gland acini and ducts, restoring normal lipid metabolism and secretion. In a NOD (Normally Ophthalmic Disorder) Sjögren's syndrome model, oral administration of 200-400 μg / kg / day of LGK974 significantly improved dry eye symptoms, including reduced corneal defects and increased tear secretion, alleviating morphological and functional damage to the meibomian glands. LGK974 provides a new targeted strategy for the treatment of dry eye syndrome, especially Sjögren's syndrome-related dry eye syndrome and meibomian gland dysfunction-related dry eye syndrome, and may become a potent and effective drug for the clinical treatment of dry eye in the future.

The application discloses a kind of drug composition of synergistic targeting MMP-9 path and STING path and application thereof, belong to the technical field of ophthalmic drugs.The drug composition includes the final concentration 5~90 μM of Marimastat, the final concentration 2.5~10 μM of SN-011, the final concentration 0.1 vol % of DMSO and sterile PBS buffer solution.The drug composition of the application can efficiently, safely treat moderate to severe dry eye, effectively improve tear film stability, repair corneal epithelial barrier, inhibit ocular surface chronic inflammation, while reducing the risk of disease recurrence.

The application provides an eye-care composition solution for relieving visual fatigue and a preparation method and application thereof, and belongs to the technical field of eye-care products. The composition solution comprises the following raw materials in mass percentage: Psidium guajava fruit powder 0.4-4%; Aronia melanocarpa fruit powder 0.8-4%; dihydroquercetin 0.01-0.2%; ergothioneine 0.01-0.06%; and the balance is water. The application takes Psidium guajava fruit powder and Aronia melanocarpa fruit powder as the main body, and is supplemented by dihydroquercetin and ergothioneine for joint action, so that the antioxidant and anti-inflammatory capacity of the eye can be improved, and the tear secretion of dry eye mice can be increased. The composition of the application produces a synergistic effect between the plant extracts and the high-efficiency active ingredients through scientific proportioning, aims to simultaneously relieve visual fatigue and improve dry eye symptoms, and has high product development value.

The present disclosure provides an ophthalmic formulation comprising: one or more pharmaceutically acceptable excipients; a pharmaceutically active compound capable of reducing the amount or deleterious effects of autoantibodies on the ocular surface, such as IgG; in particular, the present disclosure provides an ophthalmic formulation wherein the pharmaceutically active compound is capable of treating a clinical condition selected from the group consisting of inflammatory, infectious and immunological ocular surface or intraocular diseases that can cause symptoms of ocular discomfort, keratitis, dry eye disease, formation of symblepharon, shortening of the anterior chamber depth, lid margin / conjunctival keratinization, subconjunctival fibrosis, retinal gliosis and glaucoma.

The present application relates to a kind of fluorinated nanomedicine-loaded temperature-sensitive hydrogel eye drops and its preparation method and application, belong to the new auxiliary material and new dosage form technical field of drug preparation combined treatment, a kind of fluorinated nanomedicine-loaded temperature-sensitive hydrogel eye drops, including temperature-sensitive gel solution and the fluorinated nanomedicine uniformly dispersed in the temperature-sensitive gel solution;The fluorinated nanomedicine is the nanometer assembly formed by intermolecular interaction co-assembly of dexamethasone and fluorinated side chain prodrug;The structural formula of the fluorinated side chain prodrug is as shown below.The temperature-sensitive hydrogel eye drops of the present application further regulate iron death by synergistic anti-inflammatory and antioxidant effects, provide new strategy for treating dry eye.

The application provides a kind of eye drop composition and its preparation method and application, belong to ophthalmic preparation technical field.The eye drop composition used in the application includes the following components: brimonidine tartrate, hyaluronic acid, collagen, trehalose, injection water;By compounding each component, a kind of eye drop capable of realizing brimonidine tartrate sustained release, prolonging the time of antihypertensive effect, and having the characteristics of reducing blinking discomfort, long-acting moisturizing, anti-inflammatory soothing, mild antiseptic, etc. is prepared;The eye drop of the application is helpful to glaucoma, high eye pressure, dry eye, postoperative inflammation or allergy, preservative-sensitive or preservative-allergic population, improves the quality of life, relieves the disease.

The application belongs to the field of ophthalmic nano-preparations, and particularly relates to an ophthalmic poly-nitrogen-oxygen amphoteric nano-drug carrier, an ophthalmic nano-preparation and a use. The nano-drug carrier is prepared by using a random copolymer of 2-(N-oxide-N,N-diethylamino)ethyl methacrylate and butyl methacrylate, has an average particle size of 7-12 nm, and can be used for loading ophthalmic drugs such as cyclosporine A. Research shows that the nano-drug carrier has good corneal retention characteristics and corneal permeability, and after loading cyclosporine A, has a good relieving effect on corneal damage and local inflammation of dry eye model animals, and the safety of the nano-drug carrier is good, and the nano-drug carrier has a good application prospect.

A composition for use in treatment of ocular disorders is provided, comprising human keratinocyte growth factor-2 (hKGF-2) and a stabilizing agent, wherein the stabilizing agent comprises one or more of: 0.1% to 2% (w / v) mannitol or 0.01% to 0.05% (w / v) sodium hyaluronate; 0.1% to 2% (w / v) glycerol; 0.1% to 2% (w / v) trehalose or 0.5% (w / v) human serum albumin; and 0.1% to 2% (w / v) lysine hydrochloride. The compatibility between the hKGF-2 stock solution and pharmaceutical excipients was systematically studied to determine optimal concentration ranges for the stabilizing agent, surfactant, and pH-regulator. Based on these ranges, the denaturation (melting) and aggregation temperatures of hKGF-2 in the solution system were evaluated to establish an optimized formulation, in which the biological activity of hKGF-2 is maintained for an extended period. Compared with existing eye drop formulations, the hKGF-2 eye drops of the present disclosure demonstrate improved efficacy in the treatment of dry eye disease.

1. The name of the design product: packaging box (condensed time luxury freeze-dried eye mask). 2. The use of the design product: for product packaging. 3. The design points of the design product: the combination of shape and pattern. 4. The picture or photo that best indicates the design points: perspective drawing.

The application belongs to the technical field of compositions, and provides a moisturizing eye composition, a preparation method and application thereof. The moisturizing eye composition provided by the application is combined by soybean lecithin, retinol palmitate liposome, lutein, oligomeric hyaluronic acid and ethylenediaminetetraacetic acid in a specific ratio, and good synergies can be achieved among the components, the effect of relieving asthenopia, protecting eyesight and maintaining normal vision is improved, and the effect of improving and relieving the symptoms of dry eyes and dry eyes caused by various reasons (such as fatigue, wearing contact lenses, using electronic products, overuse of eyes, etc.) is improved.

This invention relates to the field of medical image analysis technology, specifically to a method and system for dry eye detection based on multimodal prior and generalized contrastive learning. The method includes: first, acquiring typical images, descriptive text, and relationship graphs of various dry eye diseases; extracting and stitching multimodal features to construct a medical prior knowledge base; second, extracting visual features from the anterior segment of the eye image and retrieving corresponding semantic features from the knowledge base according to disease labels, then projecting and aligning the two; third, constructing a medical similarity matrix based on multimodal features, mining difficult negative samples, and performing generalized contrastive learning on positive and ordinary negative samples to train a visual feature extraction network; finally, inputting the test image into the network for tear river segmentation, calculating the tear river height and pupil-tear river distance, and combining the cosine similarity of visual features and various semantic projection features to output the probability that the test image belongs to each dry eye disease level. This invention improves the accuracy of dry eye detection.

Provided are methods of assessing future onset or progression of an ocular health condition in a subject, comprising obtaining a tear fluid sample from the subject; measuring, in the tear fluid sample, concentrations of a plurality of biomarkers of a biomarker panel, wherein the biomarker panel comprises at least two or more biomarkers from the group consisting of Nerve Growth Factor (NGF), Interleukin-8 (IL-8), Tumor Necrosis Factor-Alpha (TNF-α), and Interleukin- 13 (IL-13); comparing the measured biomarker concentrations to condition-specific signature criteria; and based on the comparison, identifying the subject as having proclivity to future onset or progression of: (i) Contact Lens Discomfort (CLD) when the measured NGF concentration and the measured IL-8 concentration meet a first condition-specific signature criterion, or (ii) Dry Eye Disease (DED) when the measured NGF concentration, the measured TNF-α concentration, and the measured IL-13 concentration meet a second condition-specific signature criterion.

The application discloses an AI analysis-based tear film state monitoring system and an intelligent glasses dry eye early warning method, relates to the technical field of image processing, and comprises a pattern projection module, an ocular surface image acquisition module and a highlight suppression image generation module; the AI analysis-based tear film state monitoring system provided in the application collects eyelid edge region images by projecting a near-infrared laser speckle pattern, uses the near-infrared laser speckle pattern as a source texture, and generates a highlight suppression image by predicting a distortion field to guide the deformation of the source texture, thereby completing highlight repair; the feature information loss problem caused by the non-fixed position of the highlight reflected by the tear meniscus mirror is relieved, and stable imaging of the meibomian gland opening area under a dynamic ocular surface environment is realized.

The present application belongs to the technical field of biological medicine, and particularly relates to a composition for promoting synthesis of an OAHFA derivative family, a microneedle patch and application thereof in preventing and treating dry eye syndrome. The present application first selects an OAHFA derivative as a dry eye treatment target and relies on activation of a PPARγ signal pathway to exert drug efficacy. The composition is compounded from 0.2% to 0.5% PPARγ agonists, 2.0% to 4.0% super-long chain fatty acids and 0.3% to 0.8% ceramides, three effective components. The super-long chain fatty acids supply synthesis substrates, and the ceramides stabilize the interface. The three components synergistically improve the curative effect. The composition described in the present application adopts soluble microneedles for local administration, and the drug release rate is not less than 70% in 30 min. The effect is rapid and the puncture is painless, and the patient compliance is excellent. Local administration eliminates systemic exposure of the drug, and the drug safety is high, and there is no serious adverse reaction.

This invention belongs to the technical field of biomedicine and discloses the application of a composition comprising neo-agar oligosaccharides and astaxanthin in the preparation of formulations for the treatment of dry eye syndrome, as well as the formulation of in-situ gel eye drops and its preparation method. The composition provided by this invention specifically comprises neo-agar oligosaccharides and astaxanthin, which together constitute an organic whole, synergistically contributing to excellent ocular surface retention time and penetration efficiency. It can effectively inhibit the activation of core inflammatory pathways at low doses, reduce inflammatory cell infiltration in ocular surface tissues, promote goblet cell proliferation and epithelial repair, increase tear secretion, and improve corneal epithelial integrity. This achieves multiple effects, including anti-inflammatory properties, increased tear secretion, reduced corneal damage, promotion of ocular surface tissue repair, and improvement of corneal epithelial integrity. Furthermore, the composition exhibits excellent ocular surface biocompatibility and has very promising application prospects in the preparation of formulations for the treatment of dry eye syndrome.

The application discloses a kind of complex and its preparation method and application, including cysteine modified chitosan and peroxidase, and cysteine modified chitosan and peroxidase form stable complex;The complex provided by the application has good stability, and particle size is uniform;The complex described in the application has simple composition, and preparation and purification method are simple, production efficiency is high, it is helpful to batch production and popularization and application, cost can be controlled, and even with high concentration of the complex described in the application and eye drop is applied to mouse or rabbit eye surface, still cannot cause eyeball anomaly by safety experiment verification;The free thiol group on the surface of cysteine modified chitosan can increase the adhesion of complex on the ocular surface, so as to overcome the limitation of rapid clearance of ocular drug, significantly prolong the residence time of peroxidase on the ocular surface, greatly improve the feasibility of peroxidase in the field of dry eye treatment application.

The present invention is directed to novel modulators of the Ca2+-signaling cascade, acting as potentiators of the P2RY2 purinergic receptor and of the inositol triphosphate receptors, ITPRs. The compounds are useful in the treatment of diseases and conditions in which modulation of Ca2+-signaling plays a role, such as in some forms of spinocerebellar ataxia, and in diseases and conditions benefiting from mucosal hydration, as for example respiratory diseases and conditions, dry eye, xerostomia.